Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Preventing Oral Mucositis with Hybrid Adenoretroviral Vectors

Posted Jun 13 2010 5:00pm

Description of Invention:
Researchers at the National Institutes of Health have recently developed a novel method utilizing adenoretroviral vectors to safely and swiftly prevent oral mucositis induced by radiotherapy. This clever new method developed by National Institute of Dental and Craniofacial Research (NIDCR) researchers combines the advantages of adenoviral and retroviral vectors to efficiently shuttle into salivary glands a non-integrating vector that can produce a therapeutic protein for intermediate to long-term treatment. This approach is anticipated to result in fewer side-effects than current therapies.

The market for the treatment of mucositis, the painful inflammation and ulceration of the mucous membranes lining the digestive tract, is estimated to be in excess of $5 billion world-wide. Up to 80% of all patients receiving radiotherapy and approximately 40% of all chemotherapy patients develop oral mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis.

Applications:
  • Prevention of radiation-induced oral mucositis
  • Transduction of genes encoding secretory proteins with clinical uses for intermediate to long-term treatment (e.g., 4-8 weeks)


Advantages:
  • Safe
  • Reduced potential for side-effects
  • Efficient production of transduced genes
  • Efficient in vivo/in vitro transduction
  • Extra-chromosomal location


Development Status:
Pre-clinical

Inventors:
Changyu Zheng (NIDCR)


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The National Institute of Dental and Craniofacial Research is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact David Bradley, Ph.D. at 301-402-0540 or bradleyda@nidcr.nih.gov for more information.


Portfolios:
Gene Based Therapies
Gene Based Therapies - Therapeutics
In-vitro Data



For Additional Information Please Contact:
Patrick McCue Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: McCuepat@mail.nih.gov
Phone: 301-496-7057
Fax: 301-402-0220


Ref No: 2054

Updated: 06/2010

Post a comment
Write a comment:

Related Searches